Literature DB >> 28636275

Efficacy of aflibercept for polypoidal choroidal vasculopathy in Caucasians.

Sanaz Shoja Gharehbagh1, Yousif Subhi1,2, Torben Lykke Sørensen1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28636275     DOI: 10.1111/aos.13461

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.

Authors:  Eleftherios I Agorogiannis; Ian A Pearce; Sohraab Yadav; David G Parry; Nicholas A V Beare
Journal:  Eye (Lond)       Date:  2018-07-12       Impact factor: 3.775

Review 2.  European Prevalence of Polypoidal Choroidal Vasculopathy: A Systematic Review, Meta-Analysis, and Forecasting Study.

Authors:  Elon H C van Dijk; Jeppe K Holtz; Marc J Sirks; Janni M E Larsson; Roselie M H Diederen; Reinier O Schlingemann; Camiel J F Boon; Yousif Subhi
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

3.  Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy.

Authors:  Aaron Yap; Nancy Wang; David Squirrell
Journal:  BMC Ophthalmol       Date:  2022-07-28       Impact factor: 2.086

4.  Valsalva-Related Subretinal Hemorrhage as a Presenting Symptom of Polypoidal Choroidal Vasculopathy.

Authors:  Yousif Subhi; Torben L Sørensen
Journal:  Case Rep Ophthalmol Med       Date:  2017-09-12

5.  T-cell differentiation and CD56+ levels in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Akio Oishi; Amardeep Singh; Mogens Holst Nissen; Torben Lykke Sørensen
Journal:  Aging (Albany NY)       Date:  2017-11-20       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.